PathMaker Neurosystems Announces Completion of ALS Early-Feasibility Study of the MyoRegulator® Device for Non-Invasive Treatment of ALS

Currently, the MyoRegulator® device is under investigation as a non-invasive treatment for ALS in a second and larger clinical trial, the CALM ( C ontrolling A myotrophic L ateral Sclerosis M otor ...
Yahoo Finance

PathMaker Neurosystems Receives FDA Breakthrough Device Designation For Use of the MyoRegulator® Neuromodulation Device in ALS For Slowing the Progression of Functional Symptoms

Boston, MA and Providence, RI, Dec. 17, 2025 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a clinical-stage neurotechnology company developing a breakthrough non-invasive approach for ...
Business Wire

PathMaker Neurosystems Wins 2018 French-American Business Award for Startup of the Year

BOSTON & PARIS--(BUSINESS WIRE)--PathMaker Neurosystems Inc. (“PathMaker”), a clinical-stage bioelectronic medicine company developing non-invasive systems for the treatment of patients with chronic ...
Yahoo Finance

PathMaker Neurosystems Announces IRB Approval for DoD-funded Clinical Trial of the MyoRegulator Device in ALS

BOSTON, Feb. 04, 2025 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a clinical-stage neuromodulation company developing a breakthrough non-invasive approach to the treatment of ALS, ...
Business Wire

PathMaker Neurosystems Inc. Receives Expedited Access Pathway Designation from FDA for MyoRegulator

BOSTON--(BUSINESS WIRE)--PathMaker Neurosystems Inc. (“PathMaker”), a clinical-stage neuromodulation company developing non-invasive neurotherapy systems for the treatment of patients with neuromotor ...